A61P 13 - Drugs for disorders of the urinary system

Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
11/2002
11/07/2002	CA2443625A1 Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
11/07/2002	CA2443381A1 Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases
11/07/2002	CA2440775A1 The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use
11/07/2002	CA2408369A1 Substituted indoles as parp inhibitors
11/06/2002	EP1255112A2 Treatment of T-cell mediated diseases
11/06/2002	EP1254905A1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity
11/06/2002	EP1254898A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
11/06/2002	EP1254890A1 Derivatives of 3,3-diphenylpropylamines
11/06/2002	EP1254268A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides
11/06/2002	EP1254235A2 Drug metabolizing enzymes
11/06/2002	EP1254220A1 Human g-protein coupled 7 transmembrane receptor and polynucleotides encoding the same
11/06/2002	EP1254212A2 Methods of preparing and using a viral vector library
11/06/2002	EP1254138A1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
11/06/2002	EP1254134A2 1,3-dihydro-2h-indol-2-one derivatives,and their use as ligands for v1b or v1b and v1a arginine-vasopressin-receptors
11/06/2002	EP1254123A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
11/06/2002	EP1254120A1 Use of pyrimidine endothelin antagonists in companion animals
11/06/2002	EP1254118A2 Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives
11/06/2002	EP1254111A1 Novel vitamin d analogues
11/06/2002	EP1253966A2 Substances and agents for positively influencing collagen
11/06/2002	EP1253925A1 Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
11/06/2002	EP0781280B1 Derivatives of benzopyran and of benzothiopyran, their preparation and their use as agonists of dopaminergic receptors
11/06/2002	CN1378544A Substituted azoles compounds
11/06/2002	CN1378541A Inhibitors of c-JUN N-terminal kinase (JNK) and other protein kinases
11/06/2002	CN1378537A 嘧啶衍生物 Pyrimidine derivatives
11/06/2002	CN1378532A Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for treatment of pain
11/06/2002	CN1378531A Substituted pyrolidine-2,3,4-trion-3-oxime derivatives useful as NMDA receptor antagonists
11/06/2002	CN1378528A Use of carbonylamino derivatives against CNS disorders
11/06/2002	CN1378527A Biaryl ether derivatives useful as monoamine reuptake inhibitors
11/06/2002	CN1378459A Treatment of auto immune diseases with antagonists which bind to B cell surface markers
11/06/2002	CN1378455A Use of diterpenoid triepoxides as anti-proliferative agent
11/06/2002	CN1377880A Compound for curing vascular complication, its preparing method and treating use
11/06/2002	CN1377655A Kidney recovering liquid
11/06/2002	CN1093858C Quinoline and quinozoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia
11/05/2002	US6476044 Use of morphine derivatives as medicaments for the treatment of neuropathic problems
11/05/2002	US6476031 Quinazoline derivatives as medicaments
11/05/2002	US6476025 Phenylphennanthridines with PDE-IV inhibiting activity
11/05/2002	US6476023 Aromatic heterocyclic compounds as anti-inflammatory agents
11/05/2002	US6476022 Oxathiepino[6,5-b]dihydropyridines, and related compositions and methods
11/05/2002	US6476010 Orally administering to a post-menopausal woman a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount of l-carnitine or salts
11/05/2002	US6476008 Use of diphosphonic acids or the physiologically acceptable salts or esters thereof in the preventive treatment of after-effects resulting from enlargement or replacement of the bladder
11/05/2002	US6475997 Methods of stimulating phagocytosis
11/05/2002	US6475493 Controlled release pellet formulation
11/05/2002	CA2284717C Pet food composition
11/05/2002	CA2038379C Trifluoromethyl mercaptan and mercaptoacyl derivatives and method of using same
11/04/2002	WO2004001058A2 Transcription factor modulating compounds and methods of use thereof
11/02/2002	CA2384344A1 4-(2-pyridyl)piperizines having 5ht7 receptor agonist activity
10/2002
10/31/2002	WO2002086156A2 New polynucleotides and polypeptides of the ifn$g(a)-17 gene
10/31/2002	WO2002086087A2 Cytokine protein family
10/31/2002	WO2002086085A2 Human timp-1 antibodies
10/31/2002	WO2002086069A2 Secreted proteins
10/31/2002	WO2002085940A2 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002	WO2002085906A2 Phthalazinones derivatives useful as pde4/7 inhibitors
10/31/2002	WO2002085899A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002	WO2002085897A1 Heterocyclic compounds for aging-related and diabetic vascular complications
10/31/2002	WO2002085894A1 Arylindenopyridines with pde inhibiting activity
10/31/2002	WO2002085891A1 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
10/31/2002	WO2002085890A1 Benzimidazolone derivatives
10/31/2002	WO2002085888A1 Tetrahydropyridyl-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same
10/31/2002	WO2002085886A2 Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions
10/31/2002	WO2002085871A2 Serotonergic agents with long-acting in vivo effects
10/31/2002	WO2002085868A1 Benzoxazinone derivatives for use in the treatment of angiogenesis
10/31/2002	WO2002085859A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS
10/31/2002	WO2002085855A1 2-iminopyrrolidine derivatives
10/31/2002	WO2002085850A1 Cyclic amidine derivative
10/31/2002	WO2002085839A1 Fused bicyclic or tricyclic amino acids
10/31/2002	WO2002085827A1 Extract from the pods of lupin seeds containing lupeol
10/31/2002	WO2002085459A2 Antiangiogenic combination therapy for the treatment of cancer
10/31/2002	WO2002085458A2 Use of nk-1 receptor antagonists against benign prostatic hyperplasia
10/31/2002	WO2002085392A1 Method for using puerariae radix, puerariae radix flavone extract and preparation containing puerarin in the prevention and treatment of new indications
10/31/2002	WO2002085387A2 A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions
10/31/2002	WO2002085386A2 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue
10/31/2002	WO2002085385A2 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa
10/31/2002	WO2002085384A2 Lubricious coatings for substrates
10/31/2002	WO2002085381A1 Method for treating gout and binding uric acid
10/31/2002	WO2002085378A1 Low salt forms of polyallylamine
10/31/2002	WO2002085368A2 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
10/31/2002	WO2002085363A1 Remedial agent for glomerular disease
10/31/2002	WO2002085361A1 Benzimidazolone compounds
10/31/2002	WO2002085357A1 Nociceptin analogs
10/31/2002	WO2002085354A1 Spiroindene and spiroindane compounds
10/31/2002	WO2002085351A1 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
10/31/2002	WO2002085348A1 Use of rare earth compounds for the prevention of kidney stone disease
10/31/2002	WO2002085299A2 Therapeutic treatments using the direct application of antimicrobial metal compositions
10/31/2002	WO2002070565A9 High-affinity antagonists of elr-cxc chemokines
10/31/2002	WO2002066681A9 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
10/31/2002	WO2002053564A3 Quinuclidine derivatives and their use as m3 antagonists
10/31/2002	WO2002049650A3 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
10/31/2002	WO2002043713A3 Use of weak opioids and mixed opioid agonists/antagonists for treating urinary incontinence
10/31/2002	WO2002041896A3 Use of thienopyrimidines
10/31/2002	WO2002022611A3 Caspase inhibitors and uses thereof
10/31/2002	WO2002014499A3 Claudin polypeptides
10/31/2002	WO2001053342A9 Chimeric prostate-homing peptides with pro-apoptotic activity
10/31/2002	WO2000062766A3 Uses of ppar-gamma agonists in neutrophil-induced diseases
10/31/2002	US20020161262 Use treating various medical conditions, including pain
10/31/2002	US20020161212 BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells
10/31/2002	US20020161033 Substituted 1,5-dihydropyrrol-2-one derivatives active as NMDA receptor antagonists for treatment of states of pain
10/31/2002	US20020161030 Sulpur derivatives containing a retroamide bond as inhibitors of endothelin-converting enzymes
10/31/2002	US20020161010 Treatment of various disorders associated with enhanced activity of kinase p38-alpha and/or transforming growth factor beta; antiinflammatory agents
10/31/2002	US20020161006 1,4-dihydropyridine compounds as bradykinin antagonists
10/31/2002	US20020160999 Treatment of diseases or disorders of the central nervous system

1 ... 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 ... 562